Top Markets
#1 Akedo Akedo +101.15%
#2 TENDIES TENDIES +83.99%
#3 Verus Coin Verus Coin +44.06%
#4 Threshold Network Threshold Network +41.14%
#5 Mubarak Mubarak +23.90%
#6 Bitway Bitway +19.06%
#7 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
#8 OSK OSK +16.18%
#9 MultiversX MultiversX +15.71%
#10 Kite Kite +15.59%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Rank in Stocks #17592
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Share Price
$8.16
Last synced: 2025-06-26
Market Cap
$234.57M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Regulus Therapeutics Inc. (RGLS)

Category

Healthcare
Earnings for Regulus Therapeutics Inc. (RGLS)
Earnings in Mar 2025 TTM: $-47.52M
According to Regulus Therapeutics Inc. latest financial reports the company's current earnings are $-47.52M. In 2023 the company made an earning of $-30.04M, a decrease compared to its 2022 earnings that were of $-28.32M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Regulus Therapeutics Inc. from 2010 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $-47.52M 2.51%
2024 $-46.36M 54.34%
2023 $-30.04M 6.05%
2022 $-28.32M 1.85%
2021 $-27.81M 76.78%
2020 $-15.73M -15.39%
2019 $-18.59M -61.78%
2018 $-48.65M -32.53%
2017 $-72.10M -11.90%
2016 $-81.84M 46.76%
2015 $-55.77M -1.61%
2014 $-56.68M 203.24%
2013 $-18.69M 7.31%
2012 $-17.42M 135.51%
2011 $-7.40M -52.56%
2010 $-15.59M 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -11,199.91%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -4,204.73%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 6,395.94%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 8,351.24%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH